Ironwood Pharmaceuticals, Inc. (IRWD)
USD 0.65
(-31.48%)
USD 0.65
(-31.48%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 817.36 Million USD | 82.39% |
| 2022 | 448.14 Million USD | -13.99% |
| 2021 | 521.01 Million USD | 4.92% |
| 2020 | 496.59 Million USD | 0.12% |
| 2019 | 495.99 Million USD | -6.14% |
| 2018 | 528.42 Million USD | -11.31% |
| 2017 | 595.82 Million USD | -7.35% |
| 2016 | 643.1 Million USD | 22.73% |
| 2015 | 523.99 Million USD | 113.91% |
| 2014 | 244.96 Million USD | 1.75% |
| 2013 | 240.73 Million USD | 180.4% |
| 2012 | 85.85 Million USD | -13.38% |
| 2011 | 99.12 Million USD | -30.1% |
| 2010 | 141.81 Million USD | -69.22% |
| 2009 | 460.79 Million USD | 24.16% |
| 2008 | 371.13 Million USD | 18.09% |
| 2007 | 314.28 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 769.33 Million USD | -5.88% |
| 2024 Q2 | 717.34 Million USD | -6.76% |
| 2023 Q4 | 817.36 Million USD | -3.81% |
| 2023 Q3 | 849.74 Million USD | -10.55% |
| 2023 Q2 | 949.99 Million USD | 111.85% |
| 2023 Q1 | 448.42 Million USD | 0.06% |
| 2023 FY | 817.36 Million USD | 82.39% |
| 2022 Q3 | 449.28 Million USD | 1.46% |
| 2022 Q4 | 448.14 Million USD | -0.25% |
| 2022 FY | 448.14 Million USD | -13.99% |
| 2022 Q1 | 565.59 Million USD | 8.56% |
| 2022 Q2 | 442.8 Million USD | -21.71% |
| 2021 Q3 | 499.43 Million USD | 0.8% |
| 2021 Q1 | 489.15 Million USD | -1.5% |
| 2021 FY | 521.01 Million USD | 4.92% |
| 2021 Q2 | 495.46 Million USD | 1.29% |
| 2021 Q4 | 521.01 Million USD | 4.32% |
| 2020 Q4 | 496.59 Million USD | 2.09% |
| 2020 FY | 496.59 Million USD | 0.12% |
| 2020 Q1 | 475.56 Million USD | -4.12% |
| 2020 Q2 | 480.39 Million USD | 1.02% |
| 2020 Q3 | 486.42 Million USD | 1.26% |
| 2019 FY | 495.99 Million USD | -6.14% |
| 2019 Q2 | 535.08 Million USD | -10.93% |
| 2019 Q3 | 487.39 Million USD | -8.91% |
| 2019 Q4 | 495.99 Million USD | 1.77% |
| 2019 Q1 | 600.71 Million USD | 13.68% |
| 2018 Q4 | 528.42 Million USD | -13.93% |
| 2018 FY | 528.42 Million USD | -11.31% |
| 2018 Q3 | 613.94 Million USD | -7.28% |
| 2018 Q2 | 662.16 Million USD | 12.39% |
| 2018 Q1 | 589.14 Million USD | -1.12% |
| 2017 Q2 | 700.2 Million USD | 4.25% |
| 2017 FY | 595.82 Million USD | -7.35% |
| 2017 Q3 | 642.66 Million USD | -8.22% |
| 2017 Q4 | 595.82 Million USD | -7.29% |
| 2017 Q1 | 671.68 Million USD | 4.44% |
| 2016 FY | 643.1 Million USD | 22.73% |
| 2016 Q3 | 672.52 Million USD | 8.68% |
| 2016 Q4 | 643.1 Million USD | -4.37% |
| 2016 Q1 | 512.39 Million USD | -2.21% |
| 2016 Q2 | 618.82 Million USD | 20.77% |
| 2015 Q3 | 512.96 Million USD | -0.13% |
| 2015 Q4 | 523.99 Million USD | 2.15% |
| 2015 Q1 | 237.36 Million USD | -3.1% |
| 2015 FY | 523.99 Million USD | 113.91% |
| 2015 Q2 | 513.65 Million USD | 116.4% |
| 2014 Q4 | 244.96 Million USD | 2.92% |
| 2014 Q1 | 229.92 Million USD | -4.49% |
| 2014 Q2 | 229.23 Million USD | -0.3% |
| 2014 Q3 | 238.01 Million USD | 3.83% |
| 2014 FY | 244.96 Million USD | 1.75% |
| 2013 Q1 | 266.57 Million USD | 210.49% |
| 2013 Q4 | 240.73 Million USD | -0.37% |
| 2013 Q3 | 241.63 Million USD | -1.22% |
| 2013 Q2 | 244.61 Million USD | -8.24% |
| 2013 FY | 240.73 Million USD | 180.4% |
| 2012 Q2 | 79.88 Million USD | -6.05% |
| 2012 Q1 | 85.03 Million USD | -14.22% |
| 2012 Q4 | 85.85 Million USD | 33.29% |
| 2012 Q3 | 64.41 Million USD | -19.37% |
| 2012 FY | 85.85 Million USD | -13.38% |
| 2011 Q4 | 99.12 Million USD | -6.97% |
| 2011 Q2 | 119.61 Million USD | -6.14% |
| 2011 Q1 | 127.43 Million USD | -10.14% |
| 2011 FY | 99.12 Million USD | -30.1% |
| 2011 Q3 | 106.55 Million USD | -10.92% |
| 2010 FY | 141.81 Million USD | -69.22% |
| 2010 Q4 | 141.81 Million USD | 3.89% |
| 2010 Q3 | 136.5 Million USD | -8.1% |
| 2010 Q2 | 148.53 Million USD | -0.53% |
| 2010 Q1 | 149.32 Million USD | -67.59% |
| 2009 Q4 | 460.79 Million USD | 239.72% |
| 2009 Q3 | 135.64 Million USD | 0.0% |
| 2009 FY | 460.79 Million USD | 24.16% |
| 2008 Q4 | 371.13 Million USD | 0.0% |
| 2008 FY | 371.13 Million USD | 18.09% |
| 2007 FY | 314.28 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 13.769% |
| Embecta Corp. | 2.03 Billion USD | 59.856% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | -73.291% |
| Dynavax Technologies Corporation | 375.02 Million USD | -117.951% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -23.696% |
| Pacira BioSciences, Inc. | 704.25 Million USD | -16.061% |
| PainReform Ltd. | 2.69 Million USD | -30274.136% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | -398.684% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -13213.05% |
| SCYNEXIS, Inc. | 55.45 Million USD | -1374.063% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -8787.709% |
| Cosmos Health Inc. | 30.25 Million USD | -2601.817% |
| Journey Medical Corporation | 56.49 Million USD | -1346.695% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -13213.05% |
| Safety Shot Inc | 3.89 Million USD | -20900.996% |
| Alpha Teknova, Inc. | 38.55 Million USD | -2020.225% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | -497.181% |
| Bright Green Corporation | 6.43 Million USD | -12595.791% |
| Procaps Group, S.A. | 462.06 Million USD | -76.895% |
| Theratechnologies Inc. | 98.63 Million USD | -728.646% |
| Harrow Health, Inc. | 241.75 Million USD | -238.1% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -9234.947% |
| Biofrontera Inc. | 23.13 Million USD | -3432.426% |
| DURECT Corporation | 30.4 Million USD | -2588.18% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -67.679% |
| Cronos Group Inc. | 43.73 Million USD | -1768.864% |
| OptiNose, Inc. | 194.33 Million USD | -320.597% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -1587.208% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -3796.287% |
| Organogenesis Holdings Inc. | 181.36 Million USD | -350.683% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -21568.583% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -1456.411% |
| Radius Health, Inc. | 804.29 Million USD | -1.626% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -5842.623% |
| ProPhase Labs, Inc. | 42.54 Million USD | -1821.23% |
| Phibro Animal Health Corporation | 725.54 Million USD | -12.656% |
| Procaps Group S.A. | 462.06 Million USD | -76.895% |
| Alvotech | 1.88 Billion USD | 56.583% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -5729.183% |
| Viatris Inc. | 27.21 Billion USD | 96.997% |
| Rockwell Medical, Inc. | 30.88 Million USD | -2546.746% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -804.378% |
| SIGA Technologies, Inc. | 57.97 Million USD | -1309.807% |
| Tilray Brands, Inc. | 892.11 Million USD | 8.379% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | -271.869% |
| Shineco, Inc. | 47.6 Million USD | -1617.099% |
| PetIQ, Inc. | 645.22 Million USD | -26.679% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -372256.864% |
| Incannex Healthcare Limited | 5.83 Million USD | -13920.034% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 19.819% |
| Alimera Sciences, Inc. | 107.35 Million USD | -661.376% |
| Silver Spike Investment Corp. | 3 Million USD | -27056.608% |
| Assertio Holdings, Inc. | 148.41 Million USD | -450.728% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -43010.922% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -3734.569% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -11533.476% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -9526.818% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | -371.413% |
| Hempacco Co., Inc. | 18.82 Million USD | -4242.527% |
| Talphera, Inc. | 6.29 Million USD | -12894.722% |
| Alvotech | 1.88 Billion USD | 56.583% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | -373.562% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 2.142% |
| Currenc Group, Inc. | 177.67 Million USD | -360.034% |
| Kamada Ltd. | 109.96 Million USD | -643.276% |
| Indivior PLC | 1.95 Billion USD | 58.11% |
| Evoke Pharma, Inc. | 9.64 Million USD | -8371.818% |
| Flora Growth Corp. | 17.22 Million USD | -4646.069% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -9526.818% |
| Evolus, Inc. | 209.68 Million USD | -289.804% |
| HUTCHMED (China) Limited | 536.38 Million USD | -52.384% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 6.425% |
| Akanda Corp. | 12.66 Million USD | -6351.775% |